Library: Aging Analytics Agency – Investment Digest – Longevity industry in Asia 2021
Executive summary:
Longevity Investment Digest at a Glance
This investment digest summarises key players and observations in the private equity and venture capital ecosystem, focusing on the longevity industry.
Here we have summarised information about key industry trends, more than 1,700 promising longevity companies, 50 leading investors in this sector, and more than 50 longevity-focused publicly traded corporations, outlining major investment rounds and relevant R&D trends illustrating the industry traction and readiness of institutional investors (big pharma/biotech) to potentially acquire most successful agetech and longevity biomedicine startups.
Longevity has experienced growth
The COVID-19 pandemic has facilitated not only biotech capital market development in general, but longevity sector in particular, resulting in more than 30% of growth compared to the previous year.
Longevity market growth outperforms general trend of biotech market, yet remains more volatile. Only one company in Asia made an IPO.
Longevity is now regularly embraced as a major topic of interest for panel discussions and entire conference series by top-tier finance and business media brands including The Economist, Financial Times and Bloomberg. The industry is poised to witness a quantum leap in the near future, particularly because of the impact of artificial intelligence in biomedicine R&D and in light of the upcoming paradigm shift from treatment to prevention.
Not just good medicine
The longevity market is not limited only to the anti-aging applications of life sciences, but also includes advancing sectors of the financial industry, as well as government projects (national longevity development plans). Thus, the overall market size could exceed US$25 trillion.
Most developed longevity startups are quickly becoming mature companies, and large institutional investors are being attracted into the industry, full-fledged longevity infrastructure is emerging.
There are at least 350 publicly traded corporations that can be considered as related to the longevity industry. Longevity biomedicine, fintech, and agetech industries include 16,000+ companies, 8,000+ investors, 14 sectors, and 114 sub-sectors.
The longevity financial industry includes 1,000+ corporations, 15 sectors, and 50 sub-sectors.
The longevity governance landscape includes national healthcare budgets and development plans of at least 100 governments.
The numbers presented in the graph 1 are approximate since there is no generally accepted methodology for their estimation.
See the full report for more…
Link to Full Article:: click here
Link to Source:: click here